Advanced search
Publication Cover
Biologics: Targets and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
103
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience

Patrizia Alvisi1 Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy, [email protected]Correspondence[email protected]
,
Serena Arrigo2 Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy
,
Salvatore Cucchiara3 Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy
,
Paolo Lionetti4 Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florence, Italy
,
Erasmo Miele5 Pediatric Department, Federico II University of Naples, Naples, Italy
,
Claudio Romano6 Pediatric Gastroenterology, University of Messina, Messina, Italy
,
Alberto Ravelli7 Gastroenterology and GI Endoscopy Unit, University Department of Pediatrics, Children’s Hospital, Brescia, Italy
,
Daniela Knafelz8 Hepatology and Gastroenterology Unit, Bambino Gesù Hospital, Rome, Italy
,
Stefano Martelossi9 Department of Pediatrics, Institute of Child Health, IRCSS Burlo Garofolo, Trieste, Italy
,
Graziella Guariso10 University of Padua, Padua, Italy
,
Salvatore Accomando11 Pediatric Department, University of Palermo, G di Cristina Children’s Hospital, Palermo, Italy
,
Giovanna Zuin12 Pediatric Unit, Buzzi Hospital, Milan, Italy
,
Costantino De Giacomo13 Pediatric Unit, Niguarda Hospital, Milan, Italy
,
Lucio Balzani14 Morgagni Hospital, Forlì, Italy
,
Monia Gennari15 Emergency Pediatric Department, S Orsola Hospital, Bologna, Italy
,
Marina Aloi3 Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy
& On behalf of the SIGENP IBD Working Group show all
Pages 13-21 | Published online: 03 Jan 2019

Figures & data

Table 1 Patient demographics at diagnosis and treatment before Ada

Figure 1 Kaplan–Meier analysis of probability of remaining on Ada therapy during follow-up.

Abbreviation: Ada, adalimumab.
Figure 1 Kaplan–Meier analysis of probability of remaining on Ada therapy during follow-up.

Figure 2 Rates of clinical remission, clinical response and failure of Ada in 44 children with Crohn’s disease on Ada therapy.

Abbreviation: Ada, adalimumab.
Figure 2 Rates of clinical remission, clinical response and failure of Ada in 44 children with Crohn’s disease on Ada therapy.

Figure 3 Mean PCDAI-value trend (with SD, P<0.01).

Abbreviations: Ada, adalimumab; PCDAI, Pediatric Crohn’s Disease Activity Index.
Figure 3 Mean PCDAI-value trend (with SD, P<0.01).

Figure 4 18-Month Ada-therapy follow-up in 44 patients with Crohn’s disease.

Abbreviation: Ada, adalimumab.
Figure 4 18-Month Ada-therapy follow-up in 44 patients with Crohn’s disease.

Figure 5 Rates of adalimumab discontinuation due to remission or to no response.

Figure 5 Rates of adalimumab discontinuation due to remission or to no response.

Figure 6 Mean standardized body mass index (BMI) SD score (SDS) before starting adalimumab (Ada) and during the 18-month follow-up.

Figure 6 Mean standardized body mass index (BMI) SD score (SDS) before starting adalimumab (Ada) and during the 18-month follow-up.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.